The consumption of antiarrhythmic medicines in the Netherlands stood at 2.4 units (Defined Daily Dosage) per thousand persons per day in 2023. This level is projected to remain stable from 2024 through 2028, with no year-on-year variation and a Compound Annual Growth Rate (CAGR) of 0% over the next five years.
Future trends to watch for include potential changes in healthcare policies, advancements in alternative treatments for arrhythmia, and demographic shifts affecting the prevalence of heart conditions. Monitoring these factors will be crucial in anticipating any deviations from the current consumption pattern.
